{"id":"NCT02821416","sponsor":"AstraZeneca","briefTitle":"Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics","officialTitle":"A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Multi-Centre Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-11","primaryCompletion":"2019-10-22","completion":"2019-10-22","firstPosted":"2016-07-01","resultsPosted":"2021-01-07","lastUpdate":"2021-01-07"},"enrollment":46,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"Benralizumab","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Benralizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks on allergen-induced inflammation in subjects with mild atopic asthma challenged with an inhaled allergen.","primaryOutcome":{"measure":"Change in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge","timeFrame":"From prechallenge to 7 hours post allergen challenge during week 9","effectByArm":[{"arm":"Benra 30mg q.4 Weeks","deltaMin":0.822,"sd":4.054},{"arm":"Placebo","deltaMin":6.468,"sd":9.56}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0208"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["Canada"]},"refs":{"pmids":[],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00040&amp;attachmentIdentifier=38fb2b0f-090e-4f1a-bfa3-f74c5941c69e&amp;fileName=d3250c00040-csp-4_-_Redacted_(1).pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00040&amp;attachmentIdentifier=d3ca7f3e-fb89-4822-97f4-85610a3f79cd&amp;fileName=d3250c00040-sap-v2_-_redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":["Nasopharyngitis","Headache","Bronchitis","Myalgia","Dizziness"]}}